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AbstrACt
Introduction Antipsychotic medication is effective in 
reducing acute symptoms of psychosis, but it has a range 
of potentially serious and debilitating adverse effects 
and is often disliked by patients. It is therefore essential 
it is only used when benefits outweigh harms. Although 
multiple trials conducted with people with schizophrenia 
indicate an increased risk of relapse in the short- term 
following abrupt antipsychotic discontinuation, there is 
little evidence about the long- term outcome of a gradual 
process of reduction and discontinuation on social 
functioning, relapse and other outcomes.
Methods and analysis This is a multicentre, randomised 
controlled trial involving people with schizophrenia 
and related disorders who have had more than one 
episode. Participants are randomised to have a 
clinically- supervised, gradual reduction of antipsychotic 
medication, leading to discontinuation when possible, or to 
continue with maintenance treatment. Blinded follow- up 
assessments are conducted at 6, 12 and 24 months and 
the primary outcome is social functioning, measured by 
the Social Functioning Scale at 24 months. A minimum of 
134 evaluable participants provides 90% power to detect 
a five- point difference, and 206 to detect a four- point 
difference. Secondary outcomes include severe relapse 
(admission to hospital) and the study is also intended 
to detect a minimum 10% difference in severe relapse, 
which requires 402 participants, assuming a 15% loss to 
follow- up. Other secondary outcomes include all relapses, 
as identified by an independent and blinded endpoint 
committee, symptoms measured by the Positive and 
Negative Syndrome Scale, quality of life, adverse effects, 
self- rated recovery and neuropsychological measures. 
Enrolment started in 2016. The trial is scheduled to finish 
in June 2022.
Ethics and dissemination Ethical approval was initially 
obtained on 27 October 2016 (UK Research Ethics 
Committee reference 16/LO/1507). Results will be 
published in peer- reviewed journals and disseminated to 
the public.
trial registration number ISRCTN90298520. EudraCT: 
2016-000709-36. Pre- results.
IntroduCtIon
Schizophrenia and related conditions affect 
up to 1% of the population,1 and are associ-
ated with long- term suffering and disability, 
premature death, physical illness and high 
costs to individuals and society.2 Recom-
mended treatment for people with recurrent 
episodes consists of continuing antipsychotic 
medication.3 4 Current guidelines do not 
recommend attempts at reduction or discon-
tinuation of antipsychotics after the first 
episode, and in practice, antipsychotic 
strengths and limitations of this study
 ► The trial will be one of the first to provide data on 
the outcome of a gradual process of antipsychotic 
reduction and discontinuation in people with schizo-
phrenia and related disorders.
 ► The trial will provide relatively long- term outcome 
data on social functioning as well as relapse and 
other outcomes.
 ► There are likely to be some deviations from the 
planned treatment strategies.
 ► Longer- term follow- up would be desirable and will 
be initiated in the future.
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treatment is often ‘for life’. In spite of ongoing treat-
ment, many people remain functionally impaired. In one 
study 25% of people with schizophrenia had severe social 
disabilities after 15 years, and only 14% had none.5
The evidence base for long- term antipsychotic treat-
ment consists of studies showing lower relapse rates with 
maintenance treatment compared with discontinuation.6 
However, there are acknowledged methodological prob-
lems with these studies.7 In addition, several long- term 
non- randomised cohorts studies find worse outcomes in 
people who take continuous treatment compared with 
those who do not, although confounding by indication is 
likely to be relevant.8 9 Criticism of randomised controlled 
trials includes the fact that most focus on relapse and 
neglect other outcomes. Follow- up is generally short; 
only six of 65 studies included in a recent meta- analysis 
by Leucht et al6 had followed the participants up for more 
than a year, and longer duration of follow- up was found to 
be associated with less difference between maintenance 
and discontinuation.6 10 Moreover, relapse rates may have 
been inflated by abrupt discontinuation and misidenti-
fication of withdrawal- related adverse effects.11 12 Some 
evidence suggests gradual discontinuation may reduce 
risk of relapse compared with abrupt discontinuation,13 
although this difference was not confirmed in the analysis 
by Leucht et al.6 However, the average taper of 28 days for 
gradual medication withdrawal may not have prevented 
discontinuation- related effects in those people who had 
been taking antipsychotics for many years.
Long- term antipsychotic medication is associ-
ated with potentially serious physical complications, 
including diabetes, tardive dyskinesia and cardiovascular 
disease.14–17 Other adverse effects, such as sexual dysfunc-
tion, sedation, emotional blunting and akathisia may be 
debilitating and unpleasant.18–20 Previous research has 
found that many patients find the adverse effects of anti-
psychotics burdensome, and would like to try and discon-
tinue the treatment at some stage.21–23
There are few long- term follow- ups of people from 
randomised studies of antipsychotic discontinuation. 
A 7 year follow- up of an 18 month open trial conducted 
with people with first episode psychosis found that assign-
ment to a gradual antipsychotic reduction programme 
was associated with better rates of social recovery and 
equal rates of relapse compared with maintenance treat-
ment.24 Improved levels of neurocognitive performance 
exhibited by those randomised to antipsychotic reduction 
at 18 months suggest a possible mechanism for the long- 
term differences in functional outcome.25 In contrast, 
recent data from a 10 year follow- up of a 1 year, placebo- 
controlled trial of quetiapine in people with first- episode 
psychosis reported higher rates of a composite ‘poor 
outcome’ in people originally randomised to placebo. 
There were no differences, however, in overall symptom 
measures, social functioning or quality of life.26
Therefore, although continuing antipsychotic treat-
ment has become the norm, it remains unclear whether 
it has an optimal risk- benefit balance for all people with 
psychosis or schizophrenia. In particular, more evidence 
on the effects of gradual reduction of antipsychotics on 
short and longer- term outcomes could inform practice 
in this area. Effects on social functioning are particularly 
important to study because of evidence that long- term 
antipsychotic treatment may impair social functioning, 
despite improving symptoms or reducing relapse in the 
short- term.24 27
Further studies are currently being conducted in the 
first- episode psychosis population.28 To date, however, 
there is no study using gradual and flexible reduction 
with long- term follow- up in people with more than one 
episode.
Aims of trial
The current trial was designed to compare the benefits 
and harms of a gradual programme of dose reduction and 
discontinuation of antipsychotic treatment, under clini-
cian guidance, with maintenance treatment in people 
with a diagnosis of schizophrenia or a related disorder. 
In particular, the study was set up to test whether such a 
strategy can improve functional outcomes in people with 
recurrent or chronic psychosis while minimising the risk 
of worsening symptoms or relapse.
MEthods And AnAlysIs
study design
The trial consists of an open, parallel group randomised 
trial with concealed, individual randomisation. Randomi-
sation is conducted through an independent, internet- 
based system linked with the database (https://www. 
sealedenvelope. com/ randomisation/ internet/) with 1:1 
allocation. There are no replacements for participants 
who drop out or otherwise cannot comply with study 
procedures.
Participants and clinicians are aware of allocation, but 
outcome assessors are maintained blind to intervention 
arm as far as possible. This is achieved by nominating 
separate blinded and unblinded researchers at each site, 
and ensuring that blinded researchers are not exposed 
to discussions or written information that would reveal 
allocation. Following follow- up assessment blinded 
research staff record if they suspect they have guessed 
arm allocation.
The trial lasts for 2 years, with follow- up assessments 
conducted at 6, 12 and 24 months post randomisation. 
The trial design is presented in figure 1. Ethical approval 
includes the possibility of conducting a longer- term 
follow- up, and resources will be sought to support this at 
a later date.
Interventions
The antipsychotic reduction protocol was developed 
after consultation with professionals, academics and the 
trial’s RADAR Lived Experience Advisory Panel (LEAP). 
Both the antipsychotic reduction and maintenance proto-
cols are administered by treating psychiatrists. For those 
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Figure 1 Trial flow chart.
box 1 Eligibility criteria
Inclusion criteria
1. Aged 18 years or older.
2. A clinical and/or InternationalClassification of Diseases, 10th 
Revision, diagnosis of schizophrenia, schizoaffective disorder, delu-
sional disorder or other non- affective psychosis.
3. More than one previous episode or psychotic exacerbation, or a sin-
gle episode lasting more than 1 year.
4. Prescribed continuing antipsychotic medication.
Exclusion criteria
1. Lack of capacity to consent to the trial.
2. Insufficient command of spoken English to understand trial 
procedures.
3. Subject to a section of the Mental Health Act that includes a require-
ment to take antipsychotic medication.
4. Clinician considers there will be a serious risk of harm to self or 
others.
5. Admitted to hospital or treated by a Home Treatment or Crisis Team 
within the last month.
6. Women who have a confirmed pregnancy.
7. Women who are breastfeeding.
8. Involvement in another Investigational Medicinal Product (IMP) trial.
participants randomised to the antipsychotic medication 
reduction arm, an individualised reduction schedule is 
devised by the research team for each participant based on 
clinical judgement and adjusted according to the partici-
pant’s initial antipsychotic regimen. The dose is reduced 
incrementally every 1 or 2 months, focusing on one drug 
at a time where participants are taking more than one 
antipsychotic. The rate of reduction varies according to 
baseline dose, with most schedules aiming for discontin-
uation within 12 months, but some lasting longer where 
baseline doses are high. Treating psychiatrists are asked 
to see the participants who have been randomised to anti-
psychotic reduction approximately every 2 months for 
the duration of the reduction, to adjust the medication 
regimen and monitor mental state. The participants are 
offered the option to discontinue antipsychotic medica-
tion completely if the reduction progresses well, or to 
reduce to a very low dose, defined as the equivalent of 
2 mg of haloperidol a day or less, which is lower than the 
minimum recommended therapeutic dose for most anti-
psychotics. This is twice the dose that was defined as a 
‘low dose’ in the Dutch first episode study,24 since some 
research suggests that doses of antipsychotic medica-
tion in people with first episodes should be around half 
those recommended for people with more established 
disorders.29 30 Guidance on the antipsychotic reduction 
strategy stresses the need for flexibility, and includes a 
suggested protocol for the treatment of adverse reactions 
to withdrawal or symptom exacerbation. Participants 
randomised to maintenance treatment are requested not 
to make major reductions in their dose of antipsychotic 
medication during the trial period. Increases in dose 
are permitted within the protocol, as are changes to a 
different antipsychotic agent at the same equivalent dose 
and minor dose reductions to address side effects.
Participants are monitored by their care team according 
to usual practice. Patient records are scrutinised by 
members of the research team every 2 months to monitor 
the progress of the antipsychotic reduction and adher-
ence to the maintenance protocol. Any deviations, such as 
participants allocated to reduction not starting or halting 
their reduction, are discussed with the treating clinician. 
All changes in antipsychotic doses and use of other medi-
cations is recorded throughout the study.
Other drug treatment and interventions such as psycho-
logical therapies may be used as indicated throughout the 
trial.
Inclusion and exclusion criteria
The eligibility criteria are detailed in box 1. They are 
designed to make the trial as generalisable as possible 
to routine clinical practice, while minimising the risks of 
antipsychotic reduction in those with a history of posing a 
serious risk to self or others.
outcome measures
The primary outcome is social functioning at 2 year 
follow- up. This will be measured using the Social Func-
tioning Scale (SFS). The scale was developed in 1990, 
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Table 1 Time points at which different outcomes will be assessed
Visit number
Baseline Follow- up
1.
2. Pilot trial 3 month 
data collection
3. 6 month 
follow- up
4. 12 month 
follow- up
5. 24 month 
follow- up
6. Qualitative 
evaluation
Informed consent X X
Eligibility 
determination
X
Protocol 
assessments
A- I, L- O, 
Q, R
K C- G, I- O, 
Q, R
C- O,Q, R C- R Indicative topic 
guide with sample 
of participants and 
psychiatrists
Randomisation X
IMP administration X X X X X
Adverse events 
review
X X X X X
Medical notes review 
for prescribing 
information and 
fidelity to intervention 
protocols
X X X X X
Concomitant 
medication review
X X X X X
A, Demographic information (selected sections including weight and use of illicit drugs and alcohol); B, Diagnosis (established from clinical 
records); C, Social Functioning Scale (SFS); D, Positive and Negative Syndrome Scale (PANSS); E, Glasgow Antipsychotic Side- effect Scale 
(GASS); F, Client Satisfaction Questionnaire (CSQ-8); G, Manchester Short Assessment of quality of life (MANSA); H, Neuropsychological 
function tests; I, Medication Adherence Rating Scale (MARS-5); J, Relapse questionnaire; K, Serious Adverse Events; L, EQ- 5D- 5L; M, 
ICECAP- A; N, Client Service Receipt Inventory; O, Work Productivity and Activity Questionnaire; P, Schedule for economic data from patient 
records; Q, Questionnaire about the Process of Recovery (QPR); R, Arizona Sexual Experiences Scale (ASEX).
IMP, Investigational Medicinal Product.
and has good reliability.31 32 It can demonstrate change 
over time33–35 and distinguishes different types of antipsy-
chotic treatment.33–36 It also distinguishes between people 
in remission and those with an ongoing episode,37 people 
with long versus short duration of untreated psychosis,38 
people who convert to psychosis versus those who do not in 
an ‘ultra- high risk’ cohort34 and between people who are 
employed versus unemployed.31 This scale was preferred 
to the Groningen Social Disability Scale (GSDS),39 which 
was used in the Dutch first- episode study, because of the 
GSDS is long, requires lengthy training and has a strong 
focus on relationships rather than functioning.
The main measure of the safety of the trial is severe 
relapse which is defined as admission to acute psychi-
atric inpatient treatment. This was selected because it is 
an objective criterion, can be precisely dated and can be 
obtained through patient records. Previous antipsychotic 
withdrawal studies have defined relapse in numerous 
different ways, with no consensus on defining criteria. 
Therefore, the current trial will also use an expert 
endpoint committee to assess the presence or absence of 
relapse based on blinded information from clinical case 
notes, based on predefined criteria and guidance.
Other outcome measures include: symptoms as 
measured by the Positive and Negative Syndrome 
Scale,40 subjective quality of life as measured by the 
Manchester Short Assessment of quality of life,41 adverse 
effects of antipsychotics measured by a modified version 
of the Glasgow Antipsychotic Side- effect Scale,42 body 
weight, sexual dysfunction as measured by the Arizona 
Sexual Experiences Scale,43 Work Productivity and 
Activity Impairment - General Health (WPAI) ques-
tionnaire,44 neuropsychological function (measured by 
a brief battery of tests designed for this trial, recovery 
as measured by the Questionnaire about the Process of 
Recovery,45 ICECAP- A (quality of life) and EQ- 5D- 5L 
(quality of life).
In addition, process data will be collected, including 
dose of antipsychotic medication (in haloperidol equiva-
lents), patient satisfaction as measured by the Client Satis-
faction Questionnaire46 and antipsychotic medication 
adherence as measured by Medication Adherence Rating 
Scale.47
Table 1 shows the time points at which each measure 
will be completed. All outcome measures are adminis-
tered by research staff who have received standardised 
training. Data collected during assessments is stored in a 
secure online data management system provided by the 
Sponsor. Participant retention is promoted by sending 
correspondence and study newsletters to participants to 
facilitate engagement throughout the trial duration.
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recruitment
Participants are recruited from a variety of clinical teams 
within mental health services across the UK. Potential 
participants are identified initially by clinical staff or 
recruited by advertisements placed in clinical settings. 
Those who agree are sent further information about 
the study and then a baseline assessment is arranged 
after further discussion. Assessments are conducted at 
the patient’s home or in clinical premises according to 
patient preference.
risk reduction
The eligibility criteria are designed to exclude people 
with known high risks of causing harm to themselves or 
other people. In addition, the gradual nature of the anti-
psychotic reduction will enable detection and treatment 
of early signs of relapse. All participants will receive usual 
care and monitoring of their mental state and behaviour 
by their clinical team. Those randomised to antipsychotic 
reduction will have increased contact with a psychiatrist 
for the duration of the reduction, mirroring usual clinical 
practice with someone undergoing a significant reduc-
tion of medication.
Qualitative assessment
There will be a qualitative substudy involving around 20 
to 30 participants from the antipsychotic reduction group 
and around 12 clinicians with experience of delivering 
the antipsychotic reduction programme. This study has 
two aims: to collect data on participant and clinician 
experience of trial processes, and to explore in detail 
experiences of antipsychotic reduction and discontinu-
ation from the patient perspective. Participants will be 
identified towards the end of follow- up, using purposive 
sampling to obtain variation in clinical profile, experi-
ence of reduction, completion of the antipsychotic reduc-
tion protocol and experience of relapse.
Participants will be interviewed using a semi- structured 
interview schedule developed in collaboration with the 
RADAR LEAP. This will explore patients’ experiences of 
the intervention and its impact on their mental health 
and wider lives, the acceptability of antipsychotic reduc-
tion, satisfaction with available support and responses to 
adverse events. Interviews will be conducted with early 
participants following the 24 month follow- up interviews 
so as not to confound the main trial results. Interviews 
with clinicians will explore their experiences of imple-
menting different aspects of the antipsychotic reduction 
strategy, relations with the research team, acceptability 
of medication monitoring procedures and responses to 
adverse events. The data will be analysed using thematic 
analysis.
statistical analysis
The primary outcome (SFS) will be analysed using gener-
alised mixed models, accounting for baseline and treat-
ment periods. The principal analysis will be undertaken 
using the intention to treat population, including all 
available data, without imputation. Supportive analyses 
will include analysis of different time periods, analysis 
using repeated measurements (where all subjects with 
data at one or more post intervention assessment will 
be included), exploring potential centre effects and 
making pessimistic assumptions by group on the patient 
outcome (to assess the thresholds to the impact of ‘miss-
ingness’) because of the likely pattern of data missing not 
at random.
The proportions of patients who experience a ‘severe 
relapse’ (psychiatric hospital admission) will be compared 
with survival analysis using Cox constant proportional 
hazards models and also between randomised groups 
at the two- year follow- up point. We will undertake 
supportive threshold analyses where any loss to follow- up 
will be considered according to extreme data patterns — 
for example, assuming all those who were lost in the anti-
psychotic withdrawal group had a relapse and all those 
in the maintenance group did not, and thus quantifying 
the extent of possible effects of missingness and thus the 
robustness of the main result.
A full statistical analysis plan will be completed and 
agreed prior to any analysis or unblinding of the data, 
including planned subgroup analyses and with detailed 
description of the statistical processes to be used.
Economic analysis
The economic evaluation will evaluate the cost- 
effectiveness of the antipsychotic reduction strategy 
compared with maintenance treatment over 24 months. 
The principal analysis will be the incremental cost per 
quality adjusted life year gained from the health and social 
services cost perspective using the EQ- 5D- 5L to calculate 
quality adjusted life years (QALYs) as recommended 
by National Institute for Health and Care Excellence 
(NICE).48 A secondary analysis will include the cost per 
capability adjusted life year (CALY) gained of the anti-
psychotic reduction strategy compared with maintenance 
treatment over 24 months using the ICECAP- A, argued to 
have better face validity.49 Additional sensitivity analyses 
will explore the cost- effectiveness of antipsychotic reduc-
tion compared with maintenance capturing the quality of 
life loss associated with antipsychotics side effects using 
specific disutility values for antipsychotic side effects from 
the published literature.50
The WPAI questionnaire and associated formula44 will 
be used to give a monetary value to impact on employ-
ment. Health and social care data costs using published 
sources will be used to calculate costs for the primary 
health and social care analysis. A secondary analysis will 
be conducted from a societal perspective to capture the 
impact on employment, criminal justice, benefits, family 
and close others.
All costs and outcomes will be discounted in line with 
NICE guidance at 3.5% per year. Bootstrapping will be 
used to construct CIs for total mean costs, QALYs and 
CALYs and to construct cost- effectiveness acceptability 
curves and cost- effectiveness planes. Missing data will be 
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handled in the same way as stated by the statistical analysis 
plan.
sample size calculation
The primary outcome is social functioning, measured 
using the Social Functioning Scale.31 The literature 
suggests a minimum difference of between four and five 
points would be clinically significant, since a difference 
of four to five points appears to differentiate between 
patients with good and poor outcomes.37 51 52
Using a conventional α of 5% (two- sided) and taking 
a SD of 8.8 derived from the literature,53 a sample size 
of 134 evaluable participants is required to provide 90% 
power to identify a five point difference, and a sample of 
206 is required to identify a four point difference.
The trial also aimed to establish the safety of the anti-
psychotic reduction strategy by being powered to detect 
differences in rates of ‘severe’ relapse (psychiatric hospi-
talisation), the principal safety measure. We believe that 
an increased risk of up to 10% would be acceptable to 
many clinicians and patients if it is balanced by the 
important outcomes of an improvement in social func-
tioning and reduced side effects. We derived event rates 
for hospitalisation from those reported in the Leucht et 
al6 meta- analysis of antipsychotic discontinuation studies.
We conducted a non- inferiority calculation using a 10% 
margin of difference. Using a non- inferiority boundary of 
10% event rates (severe relapse), with an alpha of 0.05, 
requires a sample size of 372 for 90% power to exclude a 
difference of 10% between groups. Adding 15% for attri-
tion brings this up to 402. The lower CI on the absolute 
scale would exclude a difference of 10% in the situation 
where non- inferiority was achieved. Four hundred and 
two participants provides 90% power to detect a differ-
ence of 3.1 points on the primary efficacy outcome (the 
SFS), including an allowance of 15% for attrition or unex-
pected challenges to the assumptions.
It is acknowledged that the non- inferiority approach 
may be unhelpful in these circumstances, as different 
people may have substantially different views on what is a 
reasonable non- inferiority boundary. Further, the assump-
tions required on issues such as the event rate for the non- 
inferiority assumption are strong, and modest changes 
in rates can have a substantial impact on the statistical 
power of the study making the proposed non- inferiority 
boundary unhelpful in certain circumstances. Thus the 
principal aim of the study with regards to severe relapse 
is to provide a robust estimate of the event rates in each 
randomised condition, and the difference between them, 
describing measurement error with appropriate CIs in 
order to allow individual patients and their clinicians to 
make an informed decision on treatment options.
PAtIEnt And PublIC InvolvEMEnt
Testing this research question is a response to a long- 
standing demand from the service user and carer 
community for an alternative to long- term antipsychotic 
medication. Many service users and carers are extremely 
concerned about the possible long- term side effects of 
antipsychotic medication. The study has four co- applicants 
with a patient or public perspective who attend project 
management meetings; a carer, a service user, an experi-
enced coordinator and researcher and a staff member of 
a relevant charity. There is also a LEAP, made up of people 
with expertise in antipsychotic medication through 
personal use or as a carer for someone with psychosis. It 
meets regularly to discuss the progress of the study and 
to contribute to its development, for example, advising 
on the antipsychotic reduction strategy. The LEAP will be 
particularly involved in the qualitative study as part of the 
process evaluation. They will also be involved in providing 
feedback on study outputs including a regular newsletter 
and disseminating research results. Results of the study 
will be disseminated to participants at their request.
MonItorIng
The trial is monitored by a representative of the Sponsor 
according to the agreed trial- specific monitoring plan. 
A Data Safety and Monitoring Board (DSMB) and 
Programme Steering Committee provide independent 
oversight of the trial. The DSMB safeguards the interests 
of trial participants by assessing the safety and efficacy 
of the interventions during the trial, and monitoring its 
conduct and it makes recommendations to the steering 
committee. There will be no formal interim analysis, 
but the DSMB will continually review all adverse events 
data. The trial will be stopped if it is judged that there is 
a substantial increase in serious adverse events that are 
likely to be related to the intervention.
sAfEty And AdvErsE EvEnts
All adverse events are recorded with a description of the 
event, and are assessed for severity, causality, expected-
ness and seriousness.
EthICs And dIssEMInAtIon
The trial was registered with the International Standard 
Randomised Controlled Trials register on 7 February 
2017 and with  ClinicalTrials. gov on 15 June 2018. All trial 
data is handled according to the UK Data Protection Act 
1998. Substantial protocol amendments are documented 
and submitted for ethical and regulatory approval prior 
to implementation.
Written informed consent is obtained prior to partic-
ipation in the trial, following a full explanation of the 
aims, methods, anticipated benefits and hazards of the 
trial. A formal assessment of each participant’s capacity to 
provide consent is completed first. Consent is an ongoing 
process and researchers ask participants for verbal 
consent at each follow- up time point.
Results will be published in peer- reviewed journals and 
disseminated to the public and the media. All contributors 
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must meet the ‘Authorship Criteria’, as recommended by 
The International Committee of Medical Journal Editors.
Current trial status
Recruitment started in March 2016 and will continue 
until 2020.
dIsCussIon
Better evidence is required about the balance of risks 
and benefits of a supported programme of antipsychotic 
reduction and discontinuation under the guidance of a 
clinician for the many people who have a diagnosis of 
schizophrenia or recurrent psychoses. The current study 
will be the first study conducted with people with more 
than one psychotic episode to employ a gradual and 
supported method of antipsychotic reduction, to look at 
a wide range of outcomes giving priority to social func-
tioning and to follow people up for a reasonable dura-
tion. Further follow- ups are envisaged after the official 
end of the trial in order to provide data on longer- term 
outcomes.
The Dutch first- episode study suggested that long- term 
outcomes after a period of antipsychotic dose reduction 
differ from short- term outcomes.24 54 Although relapse 
rates are increased initially compared with maintenance 
treatment, over time these equalise. Social functioning, 
which was not affected in the short- term, was considerably 
improved by the time of the 7 year follow- up assessment. 
Social functioning is a measure of independence and 
personal efficacy. If the current trial results in improve-
ments in social functioning this could reduce an individu-
al’s reliance on services and produce significant economic 
benefits. From the individual’s point of view, better social 
functioning reflects a more fulfilling and socially inte-
grated life. A strategy that can successfully reduce the use 
of antipsychotic medication is also likely to be associated 
with health benefits and improvements in quality of life 
secondary to the reduction of adverse effects.
The outcomes of the current trial will provide good 
evidence to inform patients and clinicians about the 
likely consequences of reducing and discontinuing long- 
term antipsychotic treatment in a gradual manner in a 
clinical setting. Many patients currently want to consider 
this option, but existing data on the range of relevant 
outcomes is limited. Providing further information will 
facilitate a more collaborative approach to long- term anti-
psychotic treatment.
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